Interim report for the period May 2011- January 2012

3/8/2012 2:56 AM EST

Oasmia Pharmaceutical AB
Interim report

Interim report for the period May 2011- January 2012

Uppsala, Sweden, 2012-03-08 08:56 CET (GLOBE NEWSWIRE) -- 

THE PERIOD May 1, 2011 – January 31, 2012

  -- Consolidated net sales amounted to 
€
 100 thousand (12) [1]
  -- Operating income amounted to 
€
 -5,183 thousand (-4,787)
  -- Net income after tax amounted to 
€
 -5,162 thousand (-4,995)
  -- Earnings per share was 
€
 -0.10
 (-0.12)
  -- Comprehensive income amounted to 
€
 -5,162 thousand (-4,995)



THIRD QUARTER November 1, 2011 – January 31, 2012

  -- Consolidated net sales amounted to 
€
 0 thousand
(7) 
  -- Operating income amounted to 
€
 -1,952 thousand (-1,747)
  -- Net income after tax amounted to 
€
 -1,937 thousand
(-1,756)
  -- Earnings per share was 
€
-0.03 (-0.04)
  -- Comprehensive income amounted to 
€
 -1,937 thousand
(-1,756)

  -- On-going extension of patent protection
  -- Paccal® Vet was granted MUMS-designation by the FDA for the indication
     mammary carcinoma (breast cancer in dogs)





[1]The numbers in parentheses concerns results for the corresponding period
previous year 






         Weine Nejdemo, CFO, Tel: +46 18 50 54 40 e-mail: 
www.oasmia.com